Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro

• Main Authors: Valentina S. Caputo, Nikolaos Trasanidis, Xiaolin Xiao, Mark E. Robinson, Alexia Katsarou, Kanagaraju Ponnusamy, Rab K. Prinjha, Nicholas Smithers, Aristeidis Chaidos, Holger W. Auner, Anastasios Karadimitris
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: iScience
• Subjects: Biological Sciences; Developmental Biology; Bioinformatics; Omics; Transcriptomics
• Online Access: http://www.sciencedirect.com/science/article/pii/S258900422031186X

Summary: Osteoclast (OC) development in response to nuclear factor kappa-Β ligand (RANKL) is critical for bone homeostasis in health and in disease. The early and direct chromatin regulatory changes imparted by the BET chromatin readers Brd2-4 and OC-affiliated transcription factors (TFs) during osteoclastogenesis are not known. Here, we demonstrate that in response to RANKL, early OC development entails regulation of two alternative cell fate transcriptional programmes, OC vs macrophage, with repression of the latter following activation of the former. Both programmes are regulated in a non-redundant manner by increased chromatin binding of Brd2 at promoters and of Brd4 at enhancers/super-enhancers. Myc, the top RANKL-induced TF, regulates OC development in co-operation with Brd2/4 and Max and by establishing negative and positive regulatory loops with other lineage-affiliated TFs. These insights into the transcriptional regulation of osteoclastogenesis suggest the clinical potential of selective targeting of Brd2/4 to abrogate pathological OC activation.